QUICK READ: STAT News post entitled “Early peek at data on Gilead drug suggests patients are responding to treatment” was irresponsible and had led to investors gambling on a drug that has no substantial clinical data behind it. Both Gilead and the hospital urged caution. “Information from an internal forum for research colleagues concerning work in progress was released without authorization,” said University of Chicago Medicine. “Drawing any conclusions at this point is premature and scientifically unsound.”